Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tramadol + paracetamol (Krka)
- Development stage
- Unknown
- Lead developer
- KRKA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Doreta is a fixed-dose combination (FDC) oral analgesic developed by Krka, d.d., Novo mesto. It consists of tramadol hydrochloride, a centrally acting opioid analgesic, and paracetamol (acetaminophen), a non-opioid analgesic and antipyretic. The drug is designed to treat moderate to severe pain by utilizing the synergistic effects of its two active components. Tramadol acts as a mu-opioid receptor agonist and inhibits the reuptake of serotonin and norepinephrine, while paracetamol is thought to act primarily through central inhibition of cyclooxygenase enzymes. Doreta is available in both immediate-release (IR) and prolonged-release (SR) tablet formulations and has been evaluated in clinical trials, such as the TreaSuRe study, for the treatment of acute low back pain.
- Brand names
- DoretaDoreta IRDoreta SR
- Other names
- tramadol hydrochloride + paracetamoltramadol/paracetamol
02
Targets
COXSERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on tramadol + paracetamol (Krka).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tramadol + paracetamol (Krka).